HAL (France)open access
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results
Gene therapy, 0, 1, Health-related quality of life, Hemophilia A, 2, Adeno-associated virus, Clinical trial
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 475955
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.